Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2026 19:26 ET | Source: Hagens Berman Sobol Shapiro LLP

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
March 04, 2026 10:21 ET | Source: Schall Law

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm